DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20195272

Therapeutic follow-up of postoperative patients on tramadol in the intensive care unit a tertiary African hospital: a cohort study

Metogo Mbengono Junette Arlette, Owono Etoundi Paul, Amengle Albert Ludovic, Nguidjoe Evrad Marcel, Metogo Ntsama Junie Annick, Tsafack Edmond, Ze Minkande Jacqueline

Abstract


Background: Tramadol, an analgesic, is a prodrug requiring bioactivation through cytochrome P450 enzymes (CYP450) to obtain O-desmethyltramadol (M1), its active metabolite. However, little is known on the African pharmacogenetic profile of tramadol metabolism. Hence, we aimed to study the biological efficacy of tramadol in an African population.

Methods: This was a prospective cohort study over a 3-month period carried out at intensive care unit of a Cameroonian tertiary hospital. We enrolled patients with moderate-to-severe pain surgery, who had not been administered drugs metabolized by CYP450. Immediately after surgery, 2 mg/kg of tramadol was administered intravenously every 6 hours. Pain was assessed using the visual analog scale (VAS) within the first 24 hours. Vital signs and side effects were recorded. Plasma samples were collected at 3rd and 6th hours to assay tramadol and M1 using HPLC-UV.

Results: We enrolled 30 patients with a mean age of 32 years operated for caesarean section, laparotomy and cancer surgery, under spinal and general anesthesia. Before administration of tramadol, the VAS was 6/10. The VAS decreased 4/10 to 1/10 between the 3rdand the 6th hour. There was a reduction of the respiratory rate of 3 breath cycles per minute as early as the 6th hour. Samples from 13 patients were analyzed. M1 was found in all patients; of which 4 had a slow metabolism and 3 had a faster metabolism.

Conclusions: Overall there was good correlation between the clinical and biological analgesic efficacy of tramadol.

Keywords


Tramadol, M1, Therapeutic follow-up, Postoperative pain

Full Text:

PDF

References


SFAR- Prise en charge de la douleur post opératoire chez l'adulte et l'enfant. Conférence de concensus, 1997. Available at: http://www.sfar.org/accueil/print _article.php?id_article=21. Accessed on 11 August 2019.

Gentili ME, Chauvin M. Tramadol dans la prise en charge de la douleur postopératoire : pour quelle indication ?. Le Courrier de l’algologie. 2004;3.

Poulsen L, Arendt-Nielsen L, Brøsen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Therapeutics. 1996;60(6): 636–44.

Pedersen RS, Damkier P, Brøsen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Europ J Clin Pharmacol. 2006:62(7):513–21.

Stamer UM, Lehnen K, Höthker F, Bayerer B, Wolf S, Hoeft A, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 2003;105(1-2):231–8.

Scott LJ, Perry CM. Tramadol a review of its use in perioperative pain. Drugs. 2000;60(1):139-76.

Société française d'anesthésie et de réanimation. Conférence de consensus. Recommandations du jury. Prise en charge de la douleur postopératoire chez l'adulte et l'enfant. Ann Fr Anesth Réanim. 1998;17:445-61.

McQuay H, Edwards J. Meta-analysis of single dose oral tramadol plus acetaminophen in acute postoperative pain. Eur J Anaesthesiol. 2003;28:19-22.

Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an “atypical” opioid analgesic. J Pharmacol Exp Ther. 1992;260(1):275–85.

Tewodros EW, Tesfahun CE, Mirkuzie WK. Postoperative pain management among surgically treated patients in an Ethiopian hospital. Plos One. 2014;9(7):1-9.

Xu J, Zhang XC, Lv XQ, Xu YY, Wang GX, Jiang B, et al. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients. Pharmazie. 2014;69(2):138-41.